humacyte.com - HUMA Company profit before taxes, interest and amortization

Graphic logo of humacyte.com (HUMA)

Humacyte, Inc. (HUMA) generates revenue based on patents for bioreactors and cellular technologies. Absolute operating income before depreciation and amortization illustrates this trend, where the latest parameter stands at 0.00. The development of vessels for cardiology and dialysis mitigates industry risks, although high R&D costs leave financial stability dependent on clinical trial outcomes and future sales.

Profit before payment of interest, taxes and amortization: Humacyte (HUMA) for 11/23/2025 - 11/10/2026

Humacyte (HUMA) - metric breakdowns and financial figures

- current quotes and average value forecast:
Stock Quotes Humacyte Inc.|HUMA - Consensus Target
- issuer market value details:
Market Value Humacyte|HUMA - Enterprise Value
- issuer book value statistics:
Net Assets per Share Humacyte|HUMA - Company Book Value|Market-to-Book Ratio humacyte.com|HUMA - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Ratio Humacyte, Inc.|HUMA - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Humacyte Inc|HUMA - Company Total Debt|Debts to Book Capitalization Humacyte|HUMA - Company Long-Term Debt|Company Current Liabilities Humacyte|Quick Ratio humacyte.com
- company profitability and valuation multiples indicators:
HUMA - Net Profit|Future Profit Humacyte, Inc.|HUMA - Price to Earnings Ratio|Projected Price to Earnings Ratio humacyte.com|HUMA - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio Humacyte|HUMA - Operating profit EBITDA|Net earnings per one share for the last twelve months Humacyte|HUMA - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months humacyte.com|HUMA - Earnings growth in current year|Consensus forecast of earnings per share growth for next year Humacyte, Inc.
Fundamental company valuation:HUMA (Humacyte Inc.)
Flagship merchandise of Humacyte Inc

The investment attractiveness of Humacyte, Inc. (HUMA) depends on the efficiency of managing outsourcing costs for implant production and clinical trials. By analyzing changes in EBITDA_Co, an investor can observe the actual cash flow from core operations, stripped of depreciation and taxes, which allows for the identification of cyclical fluctuations in operational activity and the determination of optimal entry points for capital investment in the company.

Competitors of Humacyte, Inc. (HUMA)

NTRA - Operating profit before deduction of amortization|SERA: Operating profit before deduction of amortization